Tenon MedicalTNON
TNON
About: Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Employees: 27
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
235% more capital invested
Capital invested by funds: $48.5K [Q3] → $163K (+$114K) [Q4]
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
50% more funds holding
Funds holding: 8 [Q3] → 12 (+4) [Q4]
0.74% more ownership
Funds ownership: 2.02% [Q3] → 2.76% (+0.74%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
168%
upside
Avg. target
$3
168%
upside
High target
$3
168%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Alliance Global Partners Scott Henry 0% 1-year accuracy 0 / 5 met price target | 168%upside $3 | Buy Initiated | 9 Apr 2025 |
Financial journalist opinion
Based on 5 articles about TNON published over the past 30 days
Neutral
Accesswire
3 weeks ago
Tenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 1,271,500 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $2.00. In a concurrent private placement (the "Private Placement" and together with the registered offering, the "Offerings"), the Company also agreed to issue to the same investor warrants to purchase up to 1,271,500 shares of its common stock (the "Common Warrants").
Neutral
Accesswire
3 weeks ago
Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 733,500 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $2.00. In a concurrent private placement (the "Private Placement" and together with the registered offering, the "Offerings"), the Company also agreed to issue to the same investor warrants to purchase up to 733,500 shares of its common stock (the "Common Warrants").
Neutral
Accesswire
3 weeks ago
Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion
~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of an expanded indication for the Catamaran® SI Joint Fusion System (the "Catamaran") for use in augmenting thoracolumbar fusion. With this approval, the Catamaran is now indicated to treat the SI joint as either a stand-alone treatment or to augment a spinal fusion.
Neutral
Seeking Alpha
4 weeks ago
Tenon Medical, Inc. (TNON) Q4 2024 Earnings Call Transcript
Tenon Medical, Inc. (NASDAQ:TNON ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Steve Foster - President and CEO Kevin Williamson - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings. And welcome to the Tenon Medical Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Neutral
Accesswire
4 weeks ago
Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results
~ Full Year 2024 Revenue of $3.3 Million, a 12% Increase Compared to Prior Year ~ ~ Interim Analysis from MAINSAIL Study Reinforces Safety Profile, Effectiveness and Confirmation of Fusion ~ ~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and International Patents ~ ~ Introduced Catamaran SE Platform and Successfully Completed Initial Clinical Procedures ~ ~ National Commercial Launch of Catamaran SE in Mid-2025 ~ LOS GATOS, CA / ACCESS Newswire / March 20, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the fourth quarter and year ended December 31, 2024. Financial Results and Business Updates Fourth Quarter 2024 Results: Revenue of $0.8 million, in line with the fourth quarter of 2023.
Neutral
Accesswire
1 month ago
Tenon Medical, Inc. Announces a Warrant Inducement Transaction for $3.0 Million in Gross Proceeds
LOS GATOS, CA / ACCESS Newswire / March 11, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of Series A Warrants to purchase up to 1,222,850 shares of common stock (the "Series A Warrants") and Series B Warrants to purchase up to 1,222,850 shares of common stock (the "Series B Warrants", and together with the Series A Warrants the "Existing Warrants") at a reduced exercise price of $1.25 for gross cash proceeds of approximately $3.0 million, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
Neutral
Accesswire
1 month ago
Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office
LOS GATOS, CA / ACCESS Newswire / March 10, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today the Company has been notified by the European patent office that two additional patents directed to the novel Catamaran SI Joint Fixation Device have been approved for grant of a European patent within the European Community. "The Tenon Medical team is pleased to receive recognition from the European Community for our novel Catamaran® SI joint prostheses," commented Richard Ginn, Co-Founder and Chief Technology Officer of Tenon Medical.
Neutral
Accesswire
1 month ago
Tenon Medical, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Financial Results
LOS GATOS, CA / ACCESS Newswire / March 7, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the fourth quarter and full year 2024 ended December 31, 2024 after market close on Thursday, March 20, 2025. The Company will also hold a conference call the same day at 4:30 p.m.
Neutral
Accesswire
3 months ago
Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco
LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that Chief Financial Officer Kevin Williamson will host one-on-one investor meetings in San Francisco, CA during the week of January 13th in accordance with the 43rd Annual J.P. Morgan Healthcare Conference.
Neutral
Seeking Alpha
5 months ago
Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript
Tenon Medical, Inc. (NASDAQ:TNON ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Steven Foster - President & CEO Kevin Williamson - CFO Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings, and welcome to the Tenon Medical Third Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded.
Charts implemented using Lightweight Charts™